Answers are grounded in this paper and cite their sources.
Explores tailored surgery outcomes in head and neck squamous cell carcinoma, indicating potential benefits.
As neoadjuvant immunotherapy becomes established as a reference framework in head and neck squamous cell carcinoma management, opportunities emerge to tailor both surgical extent and timing according to treatment response. Spatial regression patterns, in addition to depth of response, should guide extent adaptation, with more conservative surgery considered for patients exhibiting a centripetal regression pattern, provided that intraoperative frozen sections from the pretreatment tumor edges are negative, potentially sparing clinically meaningful structures (e.g., avoiding mandibulectomy in oral cavity cancer). Despite promising preliminary evidence from single-center cohorts, prospective validation of the oncological feasibility and functional benefit of limited resections, supported by protocolized reporting of which structures are spared, remains necessary. Nodal management is more controversial due to frequent discordance between primary tumor and nodal response, as well as the high rate of false-positive post-treatment positron emission tomography (PET) findings. Most neoadjuvant immunotherapy trials have reported no or limited surgical delays; however, the role of response-adapted timing of surgery is under investigation, as early responders may benefit from additional immunotherapy cycles, provided that non-responders can be rapidly expedited to surgery.
No takes yet. Share an insight, caveat, or question.
Cantaffa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: